Publications of Julie Marie Vose - Research Nebraska

Publications

This view shows all the publications associated to this researcher. Select a tab to view the documents within each secion. If you are an authorized user, you can add content by selecting the Edit your profile button above. Access to this tool is managed by a project team at your institution.

340 Publications from Scopus

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

sort by year | cited by

Select All | Save icon

Export

1.
2013

Laura C. Michaelis; Ayman Saad; Xiaobo Zhong; Jennifer Le-Rademacher; Cesar O. Freytes; David I. Marks; Hillard M. Lazarus; Jennifer M. Bird; Leona Holmberg; Rammurti T. Kamble; et al.

Salvage Second Hematopoietic Cell Transplantation in Myeloma
Biology of Blood and Marrow Transplantation 2013;19(5):760-766.

1
2.
2013

Massimo Federico; Thomas Rudiger; Monica Bellei; Bharat N. Nathwani; Stefano Luminari; Bertrand Coiffier; Nancy L. Harris; Elaine S. Jaffe; Stefano A. Pileri; Kerry J. Savage; et al.

Clinicopathologic characteristics of angioimmunoblastic t-cell lymphoma: Analysis of the international peripheral t-cell lymphoma project
Journal of Clinical Oncology 2013;31(2):240-246.

0
3.
2013

Julie M. Vose

Ten years of progress in the treatment of Non-Hodgkin's Lymphoma
JNCCN Journal of the National Comprehensive Cancer Network 2013;11(1):3-4.

0
4.
2013

Julie M. Vose; Philip J. Bierman; Fausto R. Loberiza; Charles Enke; Jordan Hankins; Robert G. Bociek; Wing C. Chan; Dennis D. Weisenburger; James O. Armitage

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
Biology of Blood and Marrow Transplantation 2013;19(1):123-128.

0
5.
2013

Jonathan L. Kaufman; Christopher R. Flowers; Karen D. Rados; Gary B. Calandra; Julie M. Vose; L. Becker Hewes; Sagar Lonial; Amelia A. Langston; H. Jean Khoury; Mary Jo Lechowicz; et al.

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma
Transfusion 2013;53(1):76-84.

0
6.
2013

Anamarija M. Perry; David Crockett; Bhavana J. Dave; Pamela Althof; Lisa Winkler; Lynette M. Smith; Patricia Aoun; Wing C. Chan; Kai Fu; Timothy C. Greiner; et al.

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: Study of 39 cases
British Journal of Haematology 2013;():.

0
7.
2012

Ganapati V. Hegde; Tara M. Nordgren; Corey M. Munger; Amit K. Mittal; Philip J. Bierman; Dennis D. Weisenburger; Julie M. Vose; J. Graham Sharp; Shantaram S. Joshi

Novel therapy for therapy-resistant mantle cell lymphoma: Multipronged approach with targeting of hedgehog signaling
International Journal of Cancer 2012;131(12):2951-2960.

2
8.
2012

J A Steuter; M L H Villanueva; F R Loberiza; J O Armitage; R G Bociek; A K Ganti; S R Tarantolo; J M Vose; A Easley; P J Bierman

Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT)
Bone Marrow Transplantation 2012;():.

0
9.
2012

Andrew D. Zelenetz; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C. Byrd; Myron S. Czuczman; Luis Fayad; et al.

Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines
JNCCN Journal of the National Comprehensive Cancer Network 2012;10(12):1487-1498.

0
10.
2012

P Shaughnessy; J Uberti; S Devine; R T Maziarz; J Vose; I Micallef; E Jacobsen; J McCarty; P Stiff; A Artz; et al.

Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program
Bone Marrow Transplantation 2012;():.

0
11.
2012

Ulrike Bacher; Evgeny Klyuchnikov; Jennifer Le-Rademacher; Jeanette Carreras; Philippe Armand; Michael R. Bishop; Christopher N. Bredeson; Mitchell S. Cairo; Timothy S. Fenske; Cesar O. Freytes; et al.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: Myeloablative or reduced intensity?
Blood 2012;120(20):4256-4262.

1
12.
2012

Jorge J. Castillo; Michael Furman; Brady E. Beltrán; Michele Bibas; Mark Bower; Weina Chen; José L. Díez-Martín; Jane J. Liu; Roberto N. Miranda; Silvia Montoto; et al.

Human immunodeficiency virus-associated plasmablastic lymphoma: Poor prognosis in the era of highly active antiretroviral therapy
Cancer 2012;118(21):5270-5277.

3
13.
2012

Matthew A. Lunning; Julie M. Vose

Management of indolent lymphoma: Where are we now and where are we going
Blood Reviews 2012;26(6):279-288.

0
14.
2012

Corey M. Munger; Ganapati V. Hegde; Dennis D. Weisenburger; Julie M. Vose; Shantaram S. Joshi

Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma
Cancer Immunology, Immunotherapy 2012;61(10):1819-1832.

1
15.
2012

Anamarija M. Perry; Teresa M. Cardesa-Salzmann; Paul N. Meyer; Luis Colomo; Lynette M. Smith; Kai Fu; Timothy C. Greiner; Jan Delabie; Randy D. Gascoyne; Lisa Rimsza; et al.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
Blood 2012;120(11):2290-2296.

1
16.
2012

Julie M. Vose

Autotransplantation for mantle cell lymphoma
Cancer Journal (United States) 2012;18(5):427-431.

0
17.
2012

B.D. Cheson; N.L. Bartlett; J.M. Vose; A. Lopez-Hernandez; A.L. Seiz; A.T. Keating; S. Shamsili; K.P. Papadopoulos; Kyriakos P. Papadopoulos

Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)
Cancer 2012;118(17):4365-.

0
18.
2012

Deborah L. Darrington; Julie M. Vose

Appropriate surveillance for late complications in patients in remission from hodgkin lymphoma
Current Hematologic Malignancy Reports 2012;7(3):200-207.

0
19.
2012

Keni Gu; Dennis D. Weisenburger; Kai Fu; Wing C. Chan; Timothy C. Greiner; Patricia Aoun; Lynette M. Smith; Martin Bast; Zhongfen Liu; R. Gregory Bociek; et al.

Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation
Hematological Oncology 2012;30(3):143-149.

1
20.
2012

Zdravko Mitrovic; Anamarija M. Perry; Junji Suzumiya; James O. Armitage; Wing Y. Au; Bertrand Coiffier; Harald Holte; Elaine S. Jaffe; Emili Monserrat; Sandeep K. Rajan; et al.

The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project
American Journal of Hematology 2012;87(8):790-794.

0
21.
2012

César O. Freytes; Mei-Jie Zhang; Jeanette Carreras; Linda J. Burns; Robert Peter Gale; Luis Isola; Miguel-Angel Perales; Matthew Seftel; Julie M. Vose; Alan M. Miller; et al.

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure
Biology of Blood and Marrow Transplantation 2012;18(8):1255-1264.

2
22.
2012

Wei Li; Karen Holdeman; Javier A. Laurini; Philip J. Bierman; Julie M. Vose; Robert Gregory Bociek; James O. Armitage

Sarcoidosis mimicking recurrent lymphoma
American Journal of Hematology 2012;87(7):711-712.

0
23.
2012

Bruce D. Cheson; Nancy L. Bartlett; Julie M. Vose; Andres Lopez-Hernandez; Amanda L. Seiz; Anne T. Keating; Setareh Shamsili

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
Cancer 2012;118(12):3128-3134.

4
24.
2012

Julie M. Vose

Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management
American Journal of Hematology 2012;87(6):604-609.

2
25.
2012

Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S. Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M. Lachel; Karen Deffenbacher; Timothy C. Greiner; et al.

Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis
Blood 2012;119(21):4939-4948.

3
26.
2012

Zdravko Mitrovic; Martin Bast; Philip J. Bierman; Robert G. Bociek; Julie M. Vose; Wing C. Chan; James O. Armitage

The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma
British Journal of Haematology 2012;157(3):401-403.

0
27.
2012

M. Mian; M. Scandurra; E. Chigrinova; Y. Shen; G. Inghirami; T.C. Greiner; W.C. Chan; J.M. Vose; M. Testoni; A. Chiappella; et al.

Clinical and molecular characterization of diffuse large b-cell lymphomas with 13q14.3 deletion
Annals of Oncology 2012;23(3):729-735.

0
28.
2012

Monica Bellei; Carlos Sergio Chiattone; Stefano Luminari; Emanuela Anna Pesce; Maria Elena Cabrera; Carmino Antonio de Souza; Raul Gabús; Lucia Zoppegno; Jorge Milone; Astrid Pavlovsky; et al.

T-cell lymphomas in South America and Europe
Revista Brasileira de Hematologia e Hemoterapia 2012;34(1):42-47.

1
29.
2011

Javeed Iqbal; Paul N. Meyer; Lynette M. Smith; Nathalie A. Johnson; Julie M. Vose; Timothy C. Greiner; Joseph M. Connors; Louis M. Staudt; Lisa Rimsza; Elaine Jaffe; et al.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab
Clinical Cancer Research 2011;17(24):7785-7795.

14
30.
2011

Christopher Peters; Eli Glatstein; Julie Vose; Lisa C. Thomas; Gloria J. Morris

Early-stage Hodgkin disease in a 24-year-old woman
Seminars in Oncology 2011;38(6):705-713.

0
31.
2011

Julie M. Vose

Intensified chemotherapy for diffuse large B-cell lymphomas
The Lancet 2011;378(9806):1828-1829.

0
32.
2011

John Steuter; Dennis D. Weisenburger; R. Greg Bociek; Philip Bierman; Julie Vose; Martin Bast; Fausto Loberiza; James O. Armitage

Non-Hodgkin lymphoma of the prostate
American Journal of Hematology 2011;86(11):952-954.

0
33.
2011

Julie M. Vose

Relapsed diffuse large B-cell lymphoma: Clinical utility of cell of origin
Journal of Clinical Oncology 2011;29(31):4065-4066.

0
34.
2011

Monica Testoni; Ivo Kwee; Timothy C. Greiner; Santiago Montes-Moreno; Julie Vose; Wing C. Chan; Annalisa Chiappella; Luca Baldini; Andrés J.M. Ferreri; Gianluca Gaidano; et al.

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
British Journal of Haematology 2011;155(2):274-277.

1
35.
2011

J. Iqbal; D.D. Weisenburger; A. Chowdhury; M.Y. Tsai; G. Srivastava; T.C. Greiner; C. Kucuk; K. Deffenbacher; J. Vose; L. Smith; et al.

Erratum: Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro (Leukemia (2011) 25 (348-358) DOI:10.1038/leu.2010.255)
Leukemia 2011;25(8):1377-.

2
36.
2011

Myron S. Czuczman; Julie M. Vose; Thomas E. Witzig; Pier L. Zinzani; Rena Buckstein; Jonathan Polikoff; Ju Li; Dennis Pietronigro; Annetti Ervin-Haynes; Craig B. Reeder

The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
British Journal of Haematology 2011;154(4):477-481.

11
37.
2011

Jan Delabie; Harald Holte; Julie M. Vose; Fred Ullrich; Elaine S. Jaffe; Kerry J. Savage; Joseph M. Connors; Lisa Rimsza; Nancy L. Harris; Konrad Müller-Hermelink; et al.

Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project
Blood 2011;118(1):148-155.

24
38.
2011

Marcie R. Tomblyn; Marian Ewell; Christopher Bredeson; Brad S. Kahl; Stacey A. Goodman; Mary M. Horowitz; Julie M. Vose; Robert S. Negrin; Ginna G. Laport

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular Non-Hodgkin lymphoma beyond first complete response or first partial response
Biology of Blood and Marrow Transplantation 2011;17(7):1051-1057.

9
39.
2011

Francine M. Foss; Pier Luigi Zinzani; Julie M. Vose; Randy D. Gascoyne; Steven T. Rosen; Kensei Tobinai

Peripheral T-cell lymphoma
Blood 2011;117(25):6756-6767.

31
40.
2011

Lanfang Li; Philip Bierman; Julie Vose; Fausto Loberiza; James O. Armitage; R. Gregory Bociek

High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-hodgkin lymphoma
Clinical Lymphoma, Myeloma and Leukemia 2011;11(3):253-256.

3
41.
2011

Ekaterina Chigrinova; Michael Mian; Yulei Shen; Timothy C. Greiner; Wing C. Chan; Julie M. Vose; Giorgio Inghirami; Annalisa Chiappella; Luca Baldini; Maurilio Ponzoni; et al.

Integrated profiling of diffuse large B-cell lymphoma with 7q gain
British Journal of Haematology 2011;153(4):499-503.

2
42.
2011

Andrew D. Zelenetz; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C. Byrd; Myron S. Czuczman; Luis E. Fayad; Martha J. Glenn; et al.

Non-Hodgkin's lymphomas: Clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network 2011;9(5):484-560.

15
43.
2011

Dennis D. Weisenburger; Kerry J. Savage; Nancy Lee Harris; Randy D. Gascoyne; Elaine S. Jaffe; Kenneth A. MacLennan; Thomas Rüdiger; Stefano Pileri; Shigeo Nakamura; Bharat Nathwani; et al.

Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project
Blood 2011;117(12):3402-3408.

31
44.
2011

Jonathan W. Friedberg; Julie M. Vose; Jennifer L. Kelly; Faith Young; Steven H. Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K. Proia; Jane Liesveld; et al.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Blood 2011;117(10):2807-2812.

39
45.
2011

Ekaterina Chigrinova; Michael Mian; Marta Scandurra; Timothy C. Greiner; Wing C. Chan; Julie M. Vose; Giorgio Inghirami; Annalisa Chiappella; Luca Baldini; Maurilio Ponzoni; et al.

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome
Hematological Oncology 2011;29(1):38-41.

4
46.
2011

Jorge J. Castillo; Brady E. Beltran; Michele Bibas; Mark Bower; Jaime A. Collins; Kate Cwynarski; Jose L. Diez-Martin; Francisco Hernandez-Ilizaliturri; Steven M. Horwitz; Silvia Montoto; et al.

Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: A multicenter study
American Journal of Hematology 2011;86(3):256-261.

7
47.
2011

Jia Ruan; Peter Martin; Richard R. Furman; Shing M. Lee; Ken Cheung; Julie M. Vose; Ann LaCasce; Julia Morrison; Rebecca Elstrom; Scott Ely; et al.

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
Journal of Clinical Oncology 2011;29(6):690-697.

50
48.
2011

J. Iqbal; D.D. Weisenburger; A. Chowdhury; M.Y. Tsai; G. Srivastava; T.C. Greiner; C. Kucuk; K. Deffenbacher; J. Vose; L. Smith; et al.

Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro
Leukemia 2011;25(2):348-358.

23
49.
2011

Paul N. Meyer; Kai Fu; Timothy C. Greiner; Lynette M. Smith; Jan Delabie; Randy D. Gascoyne; German Ott; Andreas Rosenwald; Rita M. Braziel; Elias Campo; et al.

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab
Journal of Clinical Oncology 2011;29(2):200-207.

53
50.
2011

Denise M. Oliansky; Myron Czuczman; Richard I. Fisher; Frank D. Irwin; Hillard M. Lazarus; James Omel; Julie Vose; Steven N. Wolff; Roy B. Jones; Philip L. McCarthy Jr.; et al.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma: Update of the 2001 evidence-based review
Biology of Blood and Marrow Transplantation 2011;17(1):20-47.

10
51.
2011

T.E. Witzig; J.M. Vose; P.L. Zinzani; C.B. Reeder; R. Buckstein; J.A. Polikoff; R. Bouabdallah; C. Haioun; H. Tilly; P. Guo; et al.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
Annals of Oncology 2011;22(7):1622-1627.

49
52.
2011

Paul N. Meyer; Kai Fu; Timothy Greiner; Lynette Smith; Jan Delabie; Randy Gascoyne; German Ott; Andreas Rosenwald; Rita Braziel; Elias Campo; et al.

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab
American Journal of Clinical Pathology 2011;135(1):54-61.

7
53.
2010

A. Younes; J.M. Vose; A.D. Zelenetz; M.R. Smith; H.A. Burris; S.M. Ansell; J. Klein; W. Halpern; R. Miceli; E. Kumm; et al.

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
British Journal of Cancer 2010;103(12):1783-1787.

26
54.
2010

Richard R. Furman; Peter Martin; Jia Ruan; Ying-Kuen K. Cheung; Julie M. Vose; Ann S. Lacasce; Rebecca Elstrom; Morton Coleman; John P. Leonard

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma
Cancer 2010;116(23):5432-5439.

19
55.
2010

Marta Scandurra; Michael Mian; Timothy C. Greiner; Paola M.V. Rancoita; Cassio P. De Campos; Wing C. Chan; Julie M. Vose; Ekaterina Chigrinova; Giorgio Inghirami; Annalisa Chiappella; et al.

Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21
British Journal of Haematology 2010;151(3):221-231.

11
56.
2010

Julie M. Vose; Dennis D. Weisenburger; Fausto R. Loberiza; Alejandro Arevalo; Martin Bast; Joel Armitage; Philip J. Bierman; Robert G. Bociek; James O. Armitage

Late relapse in patients with diffuse large B-cell lymphoma
British Journal of Haematology 2010;151(4):354-358.

0
57.
2010

Christopher R. Flowers; Rajni Sinha; Julie M. Vose

Improving outcomes for patients with diffuse large B-cell lymphoma
CA Cancer Journal for Clinicians 2010;60(6):393-408.

29
58.
2010

Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J. Borowitz; Peter Dreger; Issa Khouri; Eduardo Olavarria; Jerald Radich; Wendy Stock; et al.

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies
Biology of Blood and Marrow Transplantation 2010;16(10):1325-1346.

10
59.
2010

Anthony J. Cannon; Deborah L. Darrington; Helen E. McIlvain; Linda K. Bauer; Julie M. Vose; James O. Armitage; Fausto R. Loberiza Jr.

Association of number of follow-up providers with outcomes in survivors of hematologic malignancies
Leukemia and Lymphoma 2010;51(10):1862-1869.

1
60.
2010

Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J. Borowitz; Peter Dreger; Issa Khouri; Homer Macapintac; Eduardo Olavarria; et al.

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes
Biology of Blood and Marrow Transplantation 2010;16(9):1187-1211.

23
61.
2010

Philip E. Johnson; George Dahlman; Kirby Eng; Rekha Garg; Scott Gottlieb; James M. Hoffman; Peyton Howell; Mohammad Jahanzeb; Shirley Johnson; Emily Mackler; et al.

NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders
JNCCN Journal of the National Comprehensive Cancer Network 2010;8(SUPPL. 7):S7-S27.

5
62.
2010

Julie M Vose

Understanding evaluation and management of primary cutaneous and systemic ALCL.
Oncology (Williston Park, N.Y.) 2010;24(7):594-.

0
63.
2010

Julie M. Vose

Understanding evaluation and management of primary cutaneous and systemic ALCL
ONCOLOGY 2010;24(7):.

1
64.
2010

Julie M. Vose

Status of Ongoing Collaborative Efforts
Seminars in Hematology 2010;47(SUPPL. 1):S18-S20.

1
65.
2010

Jonathan W. Friedberg; Jeff Sharman; John Sweetenham; Patrick B. Johnston; Julie M. Vose; Ann LaCasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P. Leonard; et al.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Blood 2010;115(13):2578-2585.

185
66.
2010

Malik E. Juweid; Julie M. Vose

Imaging in early-stage Hodgkin's lymphoma
New England Journal of Medicine 2010;362(10):962-.

1
67.
2010

Andrew D. Zelenetz; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; John C. Byrd; Myron S. Czuczman; Luis Fayad; Andres Forero; Martha J. Glenn; Jon P. Gockerman; et al.

Non-Hodgkin's lymphomas clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network 2010;8(3):288-334.

55
68.
2010

Edward A. Faber; Julie M. Vose

The role of hematopoietic stem cell transplant in follicular lymphoma
JNCCN Journal of the National Comprehensive Cancer Network 2010;8(3):337-344.

0
69.
2010

Javeed Iqbal; Dennis D. Weisenburger; Timothy C. Greiner; Julie M. Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; et al.

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
Blood 2010;115(5):1026-1036.

65
70.
2010

Owen A. O'Connor; Carol Portlock; Craig Moskowitz; Paul Hamlin; David Straus; John Gerecitano; Mithat Gonen; Otilia Dumitrescu; Debra Sarasohn; et al.

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
Clinical Cancer Research 2010;16(2):719-726.

20
71.
2010

Hillard M. Lazarus; Mei-Jie Zhang; Jeanette Carreras; Brandon M. Hayes-Lattin; Asli Selmin Ataergin; Jacob D. Bitran; Brian J. Bolwell; César O. Freytes; Robert Peter Gale; Steven C. Goldstein; et al.

A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
Biology of Blood and Marrow Transplantation 2010;16(1):35-45.

15
72.
2009

Fausto R. Loberiza Jr.; Anthony J. Cannon; Dennis D. Weisenburger; Julie M. Vose; Matt J. Moehr; Martin A. Bast; Philip J. Bierman; R. Gregory Bociek; James O. Armitage

Survival disparities in patients with lymphoma according to place of residence and treatment provider: A population-based study
Journal of Clinical Oncology 2009;27(32):5376-5382.

6
73.
2009

Thomas E. Witzig; Peter H. Wiernik; Timothy Moore; Craig Reeder; Craig Cole; Glen Justice; Henry Kaplan; Michael Voralia; Dennis Pietronigro; Kenichi Takeshita; et al.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma
Journal of Clinical Oncology 2009;27(32):5404-5409.

58
74.
2009

Timothy S. Fenske; Parameswaran N. Hari; Jeanette Carreras; Mei-Jie Zhang; Rammurti T. Kamble; Brian J. Bolwell; Mitchell S. Cairo; Richard E. Champlin; Yi-Bin Chen; César O. Freytes; et al.

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma
Biology of Blood and Marrow Transplantation 2009;15(11):1455-1464.

16
75.
2009

Kenneth C. Anderson; Melissa Alsina; William Bensinger; J. Sybil Biermann; Asher Chanan-Khan; Adam D. Cohen; Steven Devine; Benjamin Djulbegovic; Cristina Gasparetto; Carol Ann Huff; et al.

Multiple myeloma
JNCCN Journal of the National Comprehensive Cancer Network 2009;7(9):908-942.

22
76.
2009

William W. L. Choi; Dennis D. Weisenburger; Timothy C. Greiner; Miguel A. Piris; Alison H. Banham; Jan Delabie; Rita M. Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; et al.

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
Clinical Cancer Research 2009;15(17):5494-5502.

124
77.
2009

Koen van Besien; Jeanette Carreras; Philip J. Bierman; Brent R. Logan; Arturo Molina; Roberta King; Gene Nelson; Joseph W. Fay; Richard E. Champlin; et al.

Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes
Biology of Blood and Marrow Transplantation 2009;15(5):554-563.

9
78.
2009

Thomas M. Habermann; Izidore S. Lossos; Glen Justice; Julie M. Vose; Peter H. Wiernik; Kyle McBride; Kenton Wride; Annette Ervin-Haynes; Kenichi Takeshita; Dennis Pietronigro; et al.

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
British Journal of Haematology 2009;145(3):344-349.

99
79.
2009

Owen A. O'Connor; Craig Moskowitz; Carol Portlock; Paul Hamlin; David Straus; Otilia Dumitrescu; Debra Sarasohn; Mithat Gonen; John Butos; Ellen Neylon; et al.

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
British Journal of Haematology 2009;145(1):34-39.

27
80.
2009

Kai Fu; Julie M. Vose

R-CHOP improves the clinical outcomes in patients with both the GCB and non-GCB subtypes of DLBCL
American Journal of Hematology/ Oncology 2009;8(3):.

0
81.
2009

Jamil Y. Abuzetun; Fausto Loberiza; Julie Vose; Philip Bierman; R. Greg Bociek; Charles Enke; Martin Bast; Dennis Weisenburger; James O. Armitage

The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component
British Journal of Haematology 2009;144(4):531-537.

4
82.
2009

John M. Timmerman; Julie M. Vose; Debra K. Czerwinski; Wen-Kai Weng; Diane Ingolia; Martha Mayo; Dan W. Denney; Ronald Levy

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma
Leukemia and Lymphoma 2009;50(1):37-46.

15
83.
2009

Marcel P. Devetten; Parameswaran N. Hari; Jeanette Carreras; Brent R. Logan; Koen van Besien; Christopher N. Bredeson; César O. Freytes; Robert Peter Gale; John Gibson; et al.

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 2009;15(1):109-117.

27
84.
2009

Wing-Yan Au; Dennis D. Weisenburger; Tanin Intragumtornchai; Shigeo Nakamura; Won-Seog Kim; Ivy Sng; Julie Vose; James O. Armitage; Raymond Liang

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Blood 2009;113(17):3931-3937.

105
85.
2009

Kenneth R. Carson; Andrew M. Evens; Elizabeth A. Richey; Thomas M. Habermann; Daniele Focosi; John F. Seymour; Jacob Laubach; Susie D. Bawn; Leo I. Gordon; Jane N. Winter; et al.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood 2009;113(20):4834-4840.

333
86.
2009

Sharathkumar Bhagavathi; Keni Gu; Fausto R. Loberiza; Martin Bast; Julie M. Vose; Dennis D. Weisenburger

Does a diffuse growth pattern predict for survival in patients with low-grade follicular lymphoma?
Leukemia and Lymphoma 2009;50(6):900-903.

0
87.
2009

Nilesh W. Gaikwad; Li Yang; Dennis D. Weisenburger; Julie Vose; Cheryl Beseler; Eleanor G. Rogan; Ercole L. Cavalieri

Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma
Biomarkers 2009;14(7):502-512.

8
88.
2009

Jun Suzumiya; K. Ohshima; K. Tamura; K. Karube; N. Uike; K. Tobinai; R.D. Gascoyne; J.M. Vose; J.O. Armitage; D.D. Weisenburger

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: Analysis of 126 patients from the International Peripheral T-cell Lymphoma Project
Annals of Oncology 2009;20(4):715-721.

20
89.
2009

Massimo Federico; Monica Bellei; Emanuela Pesce; Emanuele Zucca; Stefano Pileri; Silvia Montoto; Dennis D. Weisenburger; Thomas Ruediger; Y.H. Ko; Raymond Liang; et al.

T-Cell project: An international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma
Revista Brasileira de Hematologia e Hemoterapia 2009;31(SUPPL. 2):21-25.

2
90.
2009

Christian Gisselbrecht; Julie Vose; Auayporn Nademanee; Alessandro M Gianni; Arnon Nagler

Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
The oncologist 2009;14 Suppl 2():41-51.

15
91.
2009

Julie M. Vose; Anthony D. Ho; Bertrand Coiffier; Paolo Corradini; Issa Khouri; Anna Sureda; Koen Van Besien; John Dipersio

Advances in mobilization for the optimization of autologous stem cell transplantation
Leukemia and Lymphoma 2009;50(9):1412-1421.

18
92.
2008

Hillard M. Lazarus; Jeanette Carreras; Christian Boudreau; Fausto R. Loberiza Jr.; James O. Armitage; Brian J. Bolwell; César O. Freytes; Robert Peter Gale; John Gibson; Gregory A. Hale; et al.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)
Biology of Blood and Marrow Transplantation 2008;14(12):1323-1333.

7
93.
2008

Ganapati V. Hegde; Katie J. Peterson; Katy Emanuel; Amit K. Mittal; Avadhut D. Joshi; John D. Dickinson; Gayathri J. Kollessery; Robert G. Bociek; Philip Bierman; Julie M. Vose; et al.

Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target
Molecular Cancer Research 2008;6(12):1928-1936.

34
94.
2008

Ibrahim T. Aldoss; Dennis D. Weisenburger; Kai Fu; Wing C. Chan; Julie M. Vose; Philip J. Bierman; R. Gregory Bociek; James O. Armitage

Adult Burkitt lymphoma: Advances in diagnosis and treatment
ONCOLOGY 2008;22(13):1508-1517.

19
95.
2008

G. Lenz; G. Wright; S.S. Dave; W. Xiao; J. Powell; H. Zhao; W. Xu; B. Tan; N. Goldschmidt; J. Iqbal; et al.

Stromal gene signatures in large-B-cell lymphomas
New England Journal of Medicine 2008;359(22):2313-2323.

300
96.
2008

Peter H. Wiernik; Izidore S. Lossos; Joseph M. Tuscano; Glen Justice; Julie M. Vose; Craig E. Cole; Wendy Lam; Kyle McBride; Kenton Wride; Dennis Pietronigro; et al.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology 2008;26(30):4952-4957.

124
97.
2008

Ken H. Young; Karen Leroy; Michael B. Møller; Gisele W. B. Colleoni; Margarita Sánchez-Beato; Fábio R. Kerbauy; Corinne Haioun; Jens C. Eickhoff; Allen H. Young; Philippe Gaulard; et al.

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study
Blood 2008;112(8):3088-3098.

51
98.
2008

Julie M. Vose

Peripheral T-Cell Non-Hodgkin's Lymphoma
Hematology/Oncology Clinics of North America 2008;22(5):997-1005.

16
99.
2008

Kai Fu; Dennis D. Weisenburger; William W. L. Choi; Kyle D. Perry; Lynette M. Smith; Xinlan Shi; Christine P. Hans; Timothy C. Greiner; Philip J. Bierman; R. Gregory Bociek; et al.

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Journal of Clinical Oncology 2008;26(28):4587-4594.

107
100.
2008

Sonali M. Smith; Koen van Besien; Jeanette Carreras; Asad Bashey; Mitchell S. Cairo; Cesar O. Freytes; Robert Peter Gale; Gregory A. Hale; Brandon Hayes-Lattin; Leona A. Holmberg; et al.

Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant
Biology of Blood and Marrow Transplantation 2008;14(8):904-912.

22
101.
2008

Kerry J. Savage; Nancy Lee Harris; Julie M. Vose; Fred Ullrich; Elaine S. Jaffe; Joseph M. Connors; Lisa Rimsza; Stefano A. Pileri; Mukesh Chhanabhai; Randy D. Gascoyne; et al.

ALK ^- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ⁺ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project
Blood 2008;111(12):5496-5504.

179
102.
2008

Peter Mclaughlin; Julie M. Vose

R-DHAP: A good small step, but not the journey's end
Leukemia and Lymphoma 2008;49(6):1019-1021.

0
103.
2008

J.M. Vose

Update on T-cell lymphoma
Annals of Oncology 2008;19(SUPPL. 4):iv74-iv76.

6
104.
2008

John P. Leonard; Stephanie A. Gregory; David G. Maloney; Julie M. Vose; Anas Younes; Andrew D. Zelenetz

Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma
Clinical Advances in Hematology and Oncology 2008;6(6):437-445.

3
105.
2008

Andrew D. Zelenetz; Ranjana H. Advani; John C. Byrd; Myron S. Czuczman; Lloyd E. Damon; Madeleine Duvic; Luis Fayad; Andres Forero; Martha J. Glenn; Jon P. Gockerman; et al.

Non-Hodgkin's lymphomas
JNCCN Journal of the National Comprehensive Cancer Network 2008;6(4):356-421.

12
106.
2008

Parameswaran Hari; Jeanette Carreras; Mei-Jie Zhang; Robert Peter Gale; Brian J. Bolwell; Christopher N. Bredeson; Linda J. Burns; Mitchell S. Cairo; César O. Freytes; et al.

Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
Biology of Blood and Marrow Transplantation 2008;14(2):236-245.

64
107.
2008

Julie M. Vose; Philip J. Bierman; Fausto R. Loberiza; James C. Lynch; Gregory R. Bociek; Dennis D. Weisenburger; James O. Armitage

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index
Biology of Blood and Marrow Transplantation 2008;14(1):36-42.

32
108.
2008

Ganapati V. Hegde; Corey M. Munger; Katy Emanuel; Avadhut D. Joshi; Timothy C. Greiner; Dennis D. Weisenburger; Julie M. Vose; Shantaram S. Joshi

Targeting of sonic hedgehog-GLI signaling: A potential strategy to improve therapy for mantle cell lymphoma
Molecular Cancer Therapeutics 2008;7(6):1450-1460.

30
109.
2008

Julie M. Vose; M. Neumann; Mildred E. Harris

International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes international T-cell lymphoma project
Journal of Clinical Oncology 2008;26(25):4124-4130.

268
110.
2007

Apar Kishor Ganti; Stephanie J. Lee; Julie M. Vose; Marcel P. Devetten; R. Gregory Bociek; James O. Armitage; Philip J. Bierman; Lori J. Maness; Elizabeth C. Reed; Fausto R. Loberiza Jr.

Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning
Journal of Clinical Oncology 2007;25(35):5643-5648.

14
111.
2007

Julie M. Vose

Current status of rituximab maintenance therapy
Clinical Advances in Hematology and Oncology 2007;5(12):968-969+1006.

1
112.
2007

Keshav Rao; Deborah L. Darrington; Joseph J. Schumacher; Marcel Devetten; Julie M. Vose; Fausto R. Loberiza Jr.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence
Biology of Blood and Marrow Transplantation 2007;13(12):1508-1514.

8
113.
2007

J. Iqbal; T.C. Greiner; K. Patel; B.J. Dave; L. Smith; J. Ji; G. Wright; W.G. Sanger; D.L. Pickering; S. Jain; et al.

Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma
Leukemia 2007;21(11):2332-2343.

59
114.
2007

Avadhut D. Joshi; Ganapati V. Hegde; John D. Dickinson; Amit K. Mittal; James C. Lynch; James D. Eudy; James O. Armitage; Philip J. Bierman; R. Gregory Bociek; et al.

ATM, CTLA4, MNDA, and HEM1 in high versus low CD38-expressing B-cell chronic lymphocytic leukemia
Clinical Cancer Research 2007;13(18):5295-5304.

16
115.
2007

J.M. Vose; M. Neumann; M.E. Harris

Therapy for T-cell non-Hodgkin's lymphoma
Leukemia Research 2007;31(SUPPL. 2):S22-S23.

0
116.
2007

Rakesh K. Singh; Michelle L. Varney; Cheryl Leutzinger; Julie M. Vose; Philip J. Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; et al.

Immune reconstitution after autologous hematopoietic transplantation with Lin^-, CD34⁺, Thy-1^lo selected or intact stem cell products
International Immunopharmacology 2007;7(8):1033-1043.

1
117.
2007

Adrian Wiestner; Mahsa Tehrani; Michael Chiorazzi; George Wright; Federica Gibellini; Kazutaka Nakayama; Hui Liu; Andreas Rosenwald; H. Konrad Muller-Hermelink; German Ott; et al.

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Blood 2007;109(11):4599-4606.

58
118.
2007

Michael J. Robertson; Brad S. Kahl; Julie M. Vose; Sven De Vos; Mary Laughlin; Patrick J. Flynn; Kendrith Rowland; Jose C. Cruz; Stuart L. Goldberg; Luna Musib; et al.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Journal of Clinical Oncology 2007;25(13):1741-1746.

132
119.
2007

Apar Kishor Ganti; Julie M. Vose; William D. Haire

Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis
Journal of Thrombosis and Thrombolysis 2007;23(2):155-158.

1
120.
2007

Julie M. Vose; Philip J. Bierman; Fausto R. Loberiza; Robert G. Bociek; Daniel Matso; James O. Armitage

Phase I trial of ⁹⁰Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
Leukemia and Lymphoma 2007;48(4):683-690.

15
121.
2007

Bruce D. Cheson; Beate Pfistner; Malik E. Juweid; Randy D. Gascoyne; Lena Specht; Sandra J. Horning; Bertrand Coiffier; Richard I. Fisher; Anton Hagenbeek; et al.

Revised response criteria for malignant lymphoma
Journal of Clinical Oncology 2007;25(5):579-586.

919
122.
2007

Maher Albitar; Julie M. Vose; Marcella M. Johnson; Kim-Ann Do; Amanda Day; Iman Jilani; Hagop Kantarjian; Michael Keating; Susan M. O'Brien; Srdan Verstovsek; et al.

Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
Leukemia Research 2007;31(2):139-145.

13
123.
2007

Kenneth C. Anderson; Melissa Alsina; William Bensinger; J. Sybil Biermann; Asher Chanan-Khan; Raymond L. Comenzo; Carlos M. De Castro; Benjamin Djulbegovic; Sherif Farag; Carol Ann Huff; et al.

Multiple myeloma: Clinical practice guidelines in oncology™
JNCCN Journal of the National Comprehensive Cancer Network 2007;5(2):118-147.

24
124.
2007

Avadhut D. Joshi; John D. Dickinson; Ganapati V. Hegde; Warren G. Sanger; James O. Armitage; Philip J. Bierman; Robert G. Bociek; Marcel P. Devetten; Julie M. Vose; et al.

Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion
Cancer Genetics and Cytogenetics 2007;172(2):120-126.

4
125.
2007

Julie Vose; Amit Panwalkar; Robert Belanger; Bertrand Coiffier; Michele Baccarani; Stephanie Gregory; Thierry Facon; Renato Fanin; Dolores Caballero; et al.

A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
Leukemia and Lymphoma 2007;48(1):39-45.

2
126.
2006

Charles L. Bennett; Andrew M. Evens; Leslie A. Andritsos; Lakshmi Balasubramanian; Mark Mai; Matthew J. Fisher; Timothy M. Kuzel; Cara Angelotta; June M. McKoy; Julie M. Vose; et al.

Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: Report from the Research on Adverse Drug Events and Reports (RADAR) project
British Journal of Haematology 2006;135(5):642-650.

70
127.
2006

Abdel-Kader Ashour; Jason L. Petersen; Mary M. McIlhaney; Julie M. Vose; Joyce C. Solheim

Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness
Hybridoma 2006;25(5):306-308.

0
128.
2006

Mary Lee H. Villanueva; Julie M. Vose

The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma
Clinical Advances in Hematology and Oncology 2006;4(7):521-530.

21
129.
2006

Sandeep S. Dave; Kai Fu; George W. Wright; Lloyd T. Lam; Philip Kluin; Evert-Jan Boerma; Timothy C. Greiner; Dennis D. Weisenburger; Andreas Rosenwald; German Ott; et al.

Molecular diagnosis of Burkitt's lymphoma
New England Journal of Medicine 2006;354(23):2431-2442.

302
130.
2006

A.K. Ganti; D.D. Weisenburger; L.M. Smith; C.P. Hans; R.G. Bociek; P.J. Bierman; J.M. Vose; J.O. Armitage

Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience
Annals of Oncology 2006;17(6):920-927.

28
131.
2006

Julie M. Vose

Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: A promising approach
Hematological Oncology 2006;24(2):47-55.

17
132.
2006

Corey M. Munger; Julie M. Vose; Shantaram S. Joshi

Dendritic cell-based therapy for mantle cell lymphoma
International Journal of Oncology 2006;28(6):1337-1343.

7
133.
2006

Willis H. Navarro; Fausto R. Loberiza Jr.; Ruta Bajorunaite; Koen van Besien; Julie M. Vose; Hillard M. Lazarus; J. Douglas Rizzo

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation 2006;12(5):541-551.

23
134.
2006

Richard I. Fisher; Bertrand Coiffier; Julie M. Vose

Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas
Clinical Advances in Hematology and Oncology 2006;4(4 SUPPL. 10):1+3.

0
135.
2006

Francine Foss; Julie M. Vose; Neumann M.; Mildred E. Harris

Purine analogues in the treatment of lymphoid malignancies
Seminars in Hematology 2006;43(SUPPL. 2):S1.

0
136.
2006

Julie M. Vose

Current and future research directions
Clinical Advances in Hematology and Oncology 2006;4(4 SUPPL. 10):8-9.

0
137.
2006

Julie M. Vose; Richard I. Fisher

Question and answer forum
Clinical Advances in Hematology and Oncology 2006;4(4 SUPPL. 10):10-.

0
138.
2006

Andrew D. Zelenetz; Ranjana H. Advani; Francis Buadi; Fernando Cabanillas; Michael A. Caligiuri; Myron S. Czuczman; Lloyd E. Damon; Luis Fayad; Ian W. Flinn; Andres Forero; et al.

Non-Hodgkin's lymphoma: Clinical practice guidelines in oncology™
JNCCN Journal of the National Comprehensive Cancer Network 2006;4(3):258-310.

19
139.
2006

Javeed Iqbal; Vishala T. Neppalli; George Wright; Bhavana J. Dave; Douglas E. Horsman; Andreas Rosenwald; James Lynch; Christine P. Hans; Dennis D. Weisenburger; Timothy C. Greiner; et al.

BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
Journal of Clinical Oncology 2006;24(6):961-968.

113
140.
2006

Timothy C. Greiner; Chiranjib Dasgupta; Vincent V. Ho; Dennis D. Weisenburger; Lynette M. Smith; James C. Lynch; Julie M. Vose; Kai Fu; James O. Armitage; et al.

Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma
Proceedings of the National Academy of Sciences of the United States of America 2006;103(7):2352-2357.

42
141.
2006

James O. Armitage; Philip J. Bierman; R. Gregory Bociek; Julie M. Vose; M. Neumann; Mildred E. Harris

Lymphoma 2006: Classification and treatment
ONCOLOGY 2006;20(3):231-239.

11
142.
2006

J.M. Vose

Chemotherapy for peripheral T-cell lymphoma
Haematologica Reports 2006;2(13):93-94.

0
143.
2005

Julie Vose

Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: A promising approach
Clinical Advances in Hematology and Oncology 2005;3(12):923-932.

3
144.
2005

Julie M. Vose; B.K. Link; M.L. Grossbard; M. Czuczman; A. Grillo-Lopez; R.I. Fisher

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
Leukemia and Lymphoma 2005;46(11):1569-1573.

22
145.
2005

Christine P. Hans; Dennis D. Weisenburger; Timothy C. Greiner; Wing C. Chan; Patricia Aoun; Gregory T. Cochran; Zenggang Pan; Lynette M. Smith; James C. Lynch; et al.

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma
Modern Pathology 2005;18(10):1377-1384.

66
146.
2005

Julie M. Vose; M. Neumann; Mildred E. Harris

Update on lymphoma management: Diffuse large B-Cell NHL
Hematology 2005;10(SUPPL. 1):10-14.

2
147.
2005

Lodovico Balducci; Harvey Jay Cohen; Paul F. Engstrom; David S. Ettinger; Jeffrey Halter; Leo I. Gordon; Krystyna Kiel; Andrew Kneier; Dean Lim; Stephen H. Petersdorf; et al.

Senior adult oncology clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network 2005;3(4):572-590.

38
148.
2005

John M. Bennett; Mark S. Kaminski; John P. Leonard; Julie M. Vose; Andrew D. Zelenetz; Susan J. Knox; Sandra Horning; Oliver W. Press; John A. Radford; Stewart M. Kroll; et al.

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I¹³¹ tositumomab
Blood 2005;105(12):4576-4582.

95
149.
2005

A.K. Ganti; P.J. Bierman; J.C. Lynch; R.G. Bociek; J.M. Vose; J.O. Armitage

Hematopoietic stem cell transplantation in mantle cell lymphoma
Annals of Oncology 2005;16(4):618-624.

39
150.
2005

Steven Z. Pavletic; Lynette M. Smith; Michael R. Bishop; James C. Lynch; Stefano R. Tarantolo; Julie M. Vose; Philip J. Bierman; Abdul Hadi; James O. Armitage; et al.

Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation
American Journal of Hematology 2005;78(4):265-274.

32
151.
2005

Apar Kishor Ganti; R. Gregory Bociek; Philip J. Bierman; Charles A. Enke; Julie M. Vose; James O. Armitage

Follicular lymphoma: Expanding therapeutic options
ONCOLOGY 2005;19(2):213-228.

15
152.
2005

Richard I. Fisher; Mark S. Kaminski; Richard L. Wahl; Susan J. Knox; Andrew D. Zelenetz; Julie M. Vose; John P. Leonard; Stewart Kroll; Stanley J. Goldsmith; Morton Coleman

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
Journal of Clinical Oncology 2005;23(30):7565-7573.

130
153.
2005

Myron S. Czuczman; Aron Thall; Thomas E. Witzig; Julie M. Vose; Anas Younes; Christos Emmanouilides; Thomas P. Miller; Joseph O. Moore; John P. Leonard; Leo I. Gordon; et al.

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
Journal of Clinical Oncology 2005;23(19):4390-4398.

102
154.
2005

Malik E. Juweid; Gregory A. Wiseman; Julie M. Vose; Justine M. Ritchie; Yusuf Menda; James E. Wooldridge; Felix M. Mottaghy; Eric M. Rohren; Norbert M. Blumstein; Alan Stolpen; et al.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
Journal of Clinical Oncology 2005;23(21):4652-4661.

184
155.
2005

Julie M. Vose; Philip J. Bierman; Charles Enke; Jordan Hankins; Gregory Bociek; James C. Lynch; James O. Armitage

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma
Journal of Clinical Oncology 2005;23(3):461-467.

111
156.
2004

Marcel P. Devetten; Julie M. Vose

Graft-versus-host disease: How to translate new insights into new therapeutic strategies
Biology of Blood and Marrow Transplantation 2004;10(12):815-825.

20
157.
2004

César O. Freytes; Fausto R. Loberiza; J. Douglas Rizzo; Asad Bashey; Christopher N. Bredeson; Mitchell S. Cairo; Robert Peter Gale; Mary M. Horowitz; Thomas R. Klumpp; et al.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry
Blood 2004;104(12):3797-3803.

62
158.
2004

Sandeep S. Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D. Gascoyne; Wing C. Chan; Richard I. Fisher; Rita M. Braziel; Lisa M. Rimsza; Thomas M. Grogan; et al.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
New England Journal of Medicine 2004;351(21):2159-2169.

578
159.
2004

J.O. Armitage; J.M. Vose; D.D. Weisenburger

Towards understanding the peripheral T-cell lymphomas
Annals of Oncology 2004;15(10):1447-1449.

40
160.
2004

Marin Nola; Steven Z. Pavletic; Dennis D. Weisenburger; Lynette M. Smith; Martin A. Bast; Julie M. Vose; James O. Armitage

Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma
American Journal of Hematology 2004;77(1):31-35.

4
161.
2004

James Z. Huang; Dennis D. Weisenburger; Julie M. Vose; Timothy C. Greiner; Patricia Aoun; Wing C. Chan; James C. Lynch; Philip J. Bierman; James O. Armitage

Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: A report of 21 cases from the Nebraska Lymphoma Study Group
Leukemia and Lymphoma 2004;45(8):1551-1557.

20
162.
2004

Javeed Iqbal; Warren G. Sanger; Douglas E. Horsman; Andreas Rosenwald; Diane L. Pickering; Bhavana Dave; Sandeep Dave; Li Xiao; Kajia Cao; Quiming Zhu; et al.

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
American Journal of Pathology 2004;165(1):159-166.

111
163.
2004

Andres Forero; Paul L. Weiden; Julie M. Vose; Susan J. Knox; Albert F. LoBuglio; Jordan Hankins; Michael L. Goris; Vincent J. Picozzi; Don B. Axworthy; Hazel B. Breitz; et al.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Blood 2004;104(1):227-236.

72
164.
2004

Francis J. Giles; Julie M. Vose; Kim-Anh Do; Marcella M. Johnson; Taghi Manshouri; Gregory Bociek; Philip J. Bierman; Susan M. O'Brien; Hagop M. Kantarjian; James O. Armitage; et al.

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
Leukemia Research 2004;28(6):595-604.

40
165.
2004

J. Vose; V. Sneller

Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma (Annals of Oncology (2003) vol. 14 (i17-i20))
Annals of Oncology 2004;15(3):541-.

0
166.
2004

Julie M. Vose; Douglas J. Rizzo; Jing Tao-Wu; James O. Armitage; Asad Bashey; Linda J. Burns; Neal Paul Christiansen; Cesar O. Freytes; Robert Peter Gale; et al.

Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
Biology of Blood and Marrow Transplantation 2004;10(2):116-127.

31
167.
2004

Julie M. Vose

Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
Oncologist 2004;9(2):160-172.

44
168.
2003

Francis J. Giles; Julie M. Vose; Kim-Anh Do; Marcella M. Johnson; Taghi Manshouri; Gregory Bociek; Philip J. Bierman; Susan M. O'Brien; Michael J. Keating; Hagop M. Kantarjian; et al.

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
British Journal of Haematology 2003;123(5):850-857.

30
169.
2003

Koen Van Besien; Fausto R. Loberiza Jr.; Ruta Bajorunaite; James O. Armitage; Asad Bashey; Linda J. Burns; Cesar O. Freytes; John Gibson; Mary M. Horowitz; David J. Inwards; et al.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
Blood 2003;102(10):3521-3529.

199
170.
2003

James Z. Huang; Dennis D. Weisenburger; Julie M. Vose; Timothy C. Greiner; Patricia Aoun; Wing C. Chan; James C. Lynch; Philip J. Bierman; James O. Armitage

Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group
Leukemia and Lymphoma 2003;44(11):1903-1910.

5
171.
2003

Philip J. Bierman; John W. Sweetenham; Fausto R. Loberiza Jr.; Goli Taghipour; Hillard M. Lazarus; J. Douglas Rizzo; Norbert Schmitz; Koen Van Besien; Julie M. Vose; Mary Horowitz; et al.

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
Journal of Clinical Oncology 2003;21(20):3744-3753.

90
172.
2003

Steven Z. Pavletic; R. Gregory Bociek; James M. Foran; Ronald J. Rubocki; Charles A. Kuszynski; James L. Wisecarver; Lori Hatcher; David M. Lucas; John C. Byrd; Michael R. Grever; et al.

Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
Transplantation 2003;76(5):877-881.

8
173.
2003

Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D. Gascoyne; Wing C. Chan; Tong Zhao; Corinne Haioun; Timothy C. Greiner; et al.

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
Journal of Experimental Medicine 2003;198(6):851-862.

363
174.
2003

Nicole Y. Fang; Timothy C. Greiner; Dennis D. Weisenburger; Wing C. Chan; Julie M. Vose; Lynette M. Smith; James O. Armitage; R. Aeryn Mayer; Brian L. Pike; Francis S. Collins; et al.

Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma
Proceedings of the National Academy of Sciences of the United States of America 2003;100(9):5372-5377.

53
175.
2003

John E. Levine; Richard E. Harris; Fausto R. Loberiza Jr.; James O. Armitage; Julie M. Vose; Koen Van Besien; Hillard M. Lazarus; Mary M. Horowitz

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma
Blood 2003;101(7):2476-2482.

62
176.
2003

Maribeth A. Hohenstein; Samuel C. Augustine; Frank Rutar; Julie M. Vose

Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab
Seminars in Oncology 2003;30(2 SUPPL. 4):39-49.

6
177.
2003

Christine P. Hans; Dennis D. Weisenburger; Julie M. Vose; Lynette M. Hock; James C. Lynch; Patricia Aoun; Timothy C. Greiner; Wing C. Chan; Robert G. Bociek; Philip J. Bierman; et al.

A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival
Blood 2003;101(6):2363-2367.

67
178.
2003

Elisabeth Vandenberghe; Carmen Ruiz De Elvira; Fausto R. Loberiza; E. Conde; A. López-Guillermo; C. Gisselbrecht; F. Guilhot; Julie M. Vose; Koen Van Biesen; et al.

Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries
British Journal of Haematology 2003;120(5):793-800.

86
179.
2003

Catherine Metayer; Rochelle E. Curtis; Julie Vose; Kathleen A. Sobocinski; Mary M. Horowitz; Smita Bhatia; Joseph W. Fay; Cesar O. Freytes; Steven C. Goldstein; et al.

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study
Blood 2003;101(5):2015-2023.

85
180.
2003

Julie M. Vose; M. Crump; H. Lazarus; C. Emmanouilides; D. Schenkein; J. Moore; S. Frankel; I. Flinn; W. Lovelace; J. Hackett; et al.

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma
Journal of Clinical Oncology 2003;21(3):514-519.

103
181.
2003

Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C. Chan; Joseph M. Connors; Elias Campo; Randy D. Gascoyne; Thomas M. Grogan; H. Konrad Muller-Hermelink; Erlend B. Smeland; et al.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Cancer Cell 2003;3(2):185-197.

440
182.
2003

Julie Vose; V. Sneller

Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma
Annals of Oncology 2003;14(SUPPL. 1):i17-i20.

12
183.
2003

Malik Juweid; Gerald L. DeNardo; Michael Graham; Julie Vose

Radioimmunotherapy: A Novel Treatment Modality for B-Cell Non-Hodgkin's Lymphoma
Cancer Biotherapy and Radiopharmaceuticals 2003;18(5):673-674.

7
184.
2003

Shantaram S. Joshi; M.R. Bishop; J.C. Lynch; S.R. Tarantolo; S. Abhyankar; P.J. Bierman; J.M. Vose; R.B. Geller; J. McGuirk; et al.

Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: Results from a randomized double-blind study
Cytotherapy 2003;5(6):542-552.

3
185.
2002

Bertrand Coiffier; Michael Pfreundschuh; Rolf Stahel; Julie Vose; Pier L. Zinzani

Aggressive lymphoma: Improving treatment outcome with rituximab
Anti-Cancer Drugs 2002;13(SUPPL. 2):S43-S50.

10
186.
2002

P.J. Bierman; J.C. Lynch; R.G. Bociek; V.L. Whalen; A. Kessinger; J.M. Vose; J.O. Armitage

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation
Annals of Oncology 2002;13(9):1370-1377.

36
187.
2002

Andreas Rosenwald; George Wright; Wing C. Chan; Joseph M. Connors; Elias Campo; Richard I. Fisher; Randy D. Gascoyne; H. Konrad Muller-Hermelink; Erlend B. Smeland; Jena M. Giltnane; et al.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
New England Journal of Medicine 2002;346(25):1937-1947.

1624
188.
2002

Julie M. Vose; Graham Sharp; Wing C. Chan; Craig Nichols; Kevin Loh; David Inwards; Robert Rifkin; Philip J. Bierman; James C. Lynch; Dennis D. Weisenburger; et al.

Autologous transplantation for aggressive non-Hodgkin's lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease
Journal of Clinical Oncology 2002;20(9):2344-2352.

51
189.
2002

Colin D. Weekes; Julie M. Vose; Jim C. Lynch; Dennis D. Weisenburger; Philip J. Bierman; Timothy Greiner; Gregory Bociek; Charles Enke; Martin Bast; Wing C. Chan; et al.

Hodgkin's disease in the elderly: Improved treatment outcome with a doxorubicin-containing regimen
Journal of Clinical Oncology 2002;20(4):1087-1093.

44
190.
2002

Julie M. Vose; Dennis D. Weisenburger; James C. Lynch; Philip J. Bierman; John C. Chan; Martin Bast; Patricia Aoun; Gregory Bociek; Timothy Greiner; James O. Armitage; et al.

CNOP for diffuse aggressive non-Hodgkin's lymphoma: The Nebraska Lymphoma Study Group experience
Leukemia and Lymphoma 2002;43(4):799-804.

5
191.
2002

Julie M Vose; Brian C-H Chiu; Bruce D Cheson; Janet Dancey; John Wright

Update on epidemiology and therapeutics for non-Hodgkin's lymphoma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():241-262.

35
192.
2002

Samuel C Augustine; Jeffrey P Norenberg; David M Colcher; Julie M Vose; Lisa S Gobar; Valorie J Dukat; Maribeth A Hohenstein; Frank J Rutar; David A Jacobson; et al.

Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice.
Journal of the American Pharmaceutical Association (Washington,D.C. : 1996) 2002;42(1):93-100.

1
193.
2001

M.S. Kaminski; A.D. Zelenetz; O.W. Press; M. Saleh; J. Leonard; L. Fehrenbacher; T.A. Lister; R.J. Stagg; G.F. Tidmarsh; S. Kroll; et al.

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Journal of Clinical Oncology 2001;19(19):3918-3928.

388
194.
2001

J.M. Vose; B.K. Link; M.L. Grossbard; M. Czuczman; A. Grillo-Lopez; P. Gilman; A. Lowe; L.A. Kunkel; R.I. Fisher

Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology 2001;19(2):389-397.

298
195.
2001

J.M. Vose; M.-J. Zhang; P.A. Rowlings; H.M. Lazarus; B.J. Bolwell; C.O. Freytes; S. Pavlovsky; A. Keating; B. Yanes; K. Van Besien; et al.

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
Journal of Clinical Oncology 2001;19(2):406-413.

123
196.
2001

Julie M Vose; Philip J Bierman; James C Lynch; Kerry Atkinson; Christopher Juttner; Elie Hanania; Gregory Bociek; James O Armitage

Transplantation of highly purified CD34⁺Thy-I⁺ hematopoietic stem cells in patients with recurrent indolent non-hodgkin's lymphoma
Biology of Blood and Marrow Transplantation 2001;7(12):680-687.

35
197.
2001

J.G. Sharp; M.R. Bishop; B. Copple; T.C. Greiner; P.L. Iversen; J.D. Jackson; S.S. Joshi; E.J. Benner; S.L. Mann; A.K. Rao; et al.

Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells
Leukemia and Lymphoma 2001;42(3):417-427.

4
198.
2001

A. Demirkazik; A. Kessinger; J.O. Armitage; P.J. Bierman; J. Lynch; J. Vose; W. Chan; J.G. Sharp

Progenitor and lymphoma cells in blood stem cell harvests: Impact on survival following transplantation
Bone Marrow Transplantation 2001;28(2):207-212.

15
199.
2001

Theresa Hahn; Steven N. Wolff; Myron Czuczman; Richard Fisher; Hillard Lazarus; Julie Vose; Lisa Warren; Richard Watt; Philip L. McCartby Jr.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review
Biology of Blood and Marrow Transplantation 2001;7(6):308-331.

40
200.
2001

F.J. Rutar; S.C. Augustine; D. Colcher; J.A. Siegel; D.A. Jacobson; M.A. Tempero; V.J. Dukat; M.A. Hohenstein; L.S. Gobar; J.M. Vose

Outpatient treatment with ¹³¹I-anti-B1 antibody: Radiation exposure to family members
Journal of Nuclear Medicine 2001;42(6):907-915.

34
201.
2001

S.A. Gregory; J. Vose; M. Modiano; K. Kraemer; R. Rifkin; A. Rubin; T. Menduni; R. Ghalie

Mitoxantrone and Fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin or mitoxantrone-containing regimen
Leukemia and Lymphoma 2001;40(3-4):315-324.

10
202.
2001

A. Khorana; P. Bunn; P. McLaughlin; J. Vose; C. Stewart; M.S. Czuczman

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma
Leukemia and Lymphoma 2001;41(1-2):77-87.

32
203.
2001

Julie M. Vose

Immunotherapy for non-Hodgkin's lymphoma
ONCOLOGY 2001;15(2):141-151.

9
204.
2001

H.M. Lazarus; F.R. Loberiza; M.-J. Zhang; J.O. Armitage; K.K. Ballen; A. Bashey; B.J. Bolwell; L.J. Burns; C.O. Freytes; R.P. Gale; et al.

Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)
Bone Marrow Transplantation 2001;27(4):387-396.

65
205.
2000

Michael R. Bishop; Stefano R. Tarantolo; Robert B. Geller; James C. Lynch; Philip J. Bierman; Z. Steven Pavletic; Julie M. Vose; Susan Kruse; Suzanne P. Dix; et al.

A randomized, double-blind trial of filgrastim (granulocyte colony- stimulating factor) versus placebo following allogeneic blood stem cell transplantation
Blood 2000;96(1):80-85.

57
206.
2000

J.M. Vose; F. Cabanillas; S. O'Brien; N. Dang; R. Drapkin; F. Foss

Infectious complications of pentostatin therapy.
Oncology (Williston Park, N.Y.) 2000;14(6 Suppl 2):41-42.

2
207.
2000

Rakesh K. Singh; Michelle L. Varney; Kazuhiko Ino; Julie M. Vose; Philip J. Bierman; James E. Talmadge

Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non- Hodgkin's lymphoma patients
Experimental Hematology 2000;28(5):499-507.

26
208.
2000

Julie M. Vose; Richard L. Wahl; Mansoor Saleh; Ama Z. Rohatiner; Susan J. Knox; John A. Radford; Andrew D. Zelenetz; George F. Tidmarsh; Robert J. Stagg; Mark S. Kaminski

Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
Journal of Clinical Oncology 2000;18(6):1316-1323.

264
209.
2000

I.S. Lossos; C.Y. Okada; R. Tibshirani; R. Warnke; J.M. Vose; T.C. Greiner; Ronald Levy

Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas
Blood 2000;95(5):1797-1803.

94
210.
2000

Dennis D. Weisenburger; Julie M. Vose; Timothy C. Greiner; James C. Lynch; Wing C. Chan; Philip J. Bierman; Bhavana J. Dave; Warren G. Sanger; James O. Armitage

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
American Journal of Hematology 2000;64(3):190-196.

86
211.
2000

Richard A. Nash; Razelle Kurzrock; John DiPersio; Julie Vose; Charles Linker; Dipnarine Maharaj; Auayporn P. Nademanee; Robert Negrin; Stephen Nimer; Howard Shulman; et al.

A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation 2000;6(1):25-34.

45
212.
2000

Julie M. Vose; Philip J. Bierman; Dennis D. Weisenburger; James C. Lynch; Gregory Bociek; Wing C. Chan; Timothy C. Greiner; James O. Armitage

Autologous Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma
Biology of Blood and Marrow Transplantation 2000;6(6):640-645.

40
213.
2000

Dennis D. Weisenburger; Randy D. Gascoyne; Philip J. Bierman; Tamara Shenkier; Douglas E. Horsman; James C. Lynch; Wing C. Chan; Timothy C. Greiner; Joseph M. Connors; et al.

Clinical significance of the t(14; 18) and BCL2 overexpression in follicular large cell lymphoma
Leukemia and Lymphoma 2000;36(5-6):513-523.

24
214.
2000

J.M. Vose

Therapeutic uses of MAbs directed against CD20
Cytotherapy 2000;2(6):455-461.

4
215.
2000

Z.S. Pavletic; E.R. Arrowsmith; P.J. Bierman; S.A. Goodman; J.M. Vose; S.R. Tarantolo; R.S. Stein; G. Bociek; J.P. Greer; C.D. Wu; et al.

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia
Bone Marrow Transplantation 2000;25(7):717-722.

80
216.
2000

Julie M. Vose; David Colcher; Lisa Gobar; Philip J. Bierman; Samuel Augustine; Margaret Tempero; Peter Leichner; James C. Lynch; David Goldenberg; James O. Armitage

Phase I/II trial of multiple dose ¹³¹Iodine-MAb LL2 (CD22) in patients with recurrent non-hodgkin's lymphoma
Leukemia and Lymphoma 2000;38(1-2):91-101.

46
217.
2000

Julie M. Vose

The Girardi/Edelson article reviewed
ONCOLOGY 2000;14(7):1074-1076.

0
218.
1999

Randy D. Gascoyne; Patricia Aoun; Daniel Wu; Mukesh Chhanabhai; Brian F. Skinnider; Timothy C. Greiner; Stephan W. Morris; Joseph M. Connors; Julie M. Vose; et al.

Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
Blood 1999;93(11):3913-3921.

305
219.
1999

Bruce D. Cheson; Sandra J. Horning; Bertrand Coiffier; Margaret A. Shipp; Richard I. Fisher; Joseph M. Connors; T. Andrew Lister; Julie Vose; Antonio Grillo-López; Anton Hagenbeek; et al.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
Journal of Clinical Oncology 1999;17(4):1244-1253.

1856
220.
1999

Ashraf A. Abou-Elella; Dennis D. Weisenburger; Julie M. Vose; Jeffrey P. Kollath; James C. Lynch; Martin A. Bast; Philip J. Bierman; Timothy C. Greiner; Wing C. Chan; James O. Armitage

Primary mediastinal large B-cell lymphoma: A clinicopathologic study of 43 patients from the Nebraska lymphoma study group
Journal of Clinical Oncology 1999;17(3):784-790.

46
221.
1999

K. Scott Baker; Bruce G. Gordon; Thomas G. Gross; Minnie A. Abromowitch; Elizabeth R. Lyden; James C. Lynch; Julie M. Vose; James O. Armitage; Peter F. Coccia; et al.

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents
Journal of Clinical Oncology 1999;17(3):825-831.

42
222.
1999

Hillard M. Lazarus; Philip A. Rowlings; Mei-Jie Zhang; Julie M. Vose; James O. Armitage; Philip J. Bierman; James L. Gajewski; Robert Peter Gale; Armand Keating; John P. Klein; et al.

Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry
Journal of Clinical Oncology 1999;17(2):534-545.

122
223.
1999

Haluk Tezcan; Julie M. Vose; Martin Bast; Philip J. Bierman; Anne Kessinger; James O. Armitage

Limited stage I and II follicular non-Hodgkin's lymphoma: The Nebraska lymphoma study group experience
Leukemia and Lymphoma 1999;34(3-4):273-285.

17
224.
1999

J.M. Vose

Antibody-targeted therapy for low-grade lymphoma
Seminars in Hematology 1999;36(4 SUPPL. 6):15-20.

28
225.
1999

M.B. Freeman; J.M. Vose; C.L. Bennett; J.R. Anderson; A. Kessinger; K. Turner; J. Pierson; M.R. Bishop; P. Bierman; J.O. Armitage

Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: Results from the University of Nebraska Medical Center 1989 to 1995
Bone Marrow Transplantation 1999;24(6):679-684.

16
226.
1999

A.G. Ageitos; M.L. Varney; P.J. Bierman; J.M. Vose; P.I. Warkentin; J.E. Talmadge

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products
Bone Marrow Transplantation 1999;23(1):63-69.

34
227.
1998

Koen Van Besien; Kathleen A. Sobocinski; Philip A. Rowlings; Sandra C. Murphy; James O. Armitage; Michael R. Bishop; Ok-Kyong Chaekal; Robert Peter Gale; John P. Klein; Hillard M. Lazarus; et al.

Allogeneic bone marrow transplantation for low-grade lymphoma
Blood 1998;92(5):1832-1836.

204
228.
1998

Z.S. Pavletic; P.J. Bierman; J.M. Vose; M.R. Bishop; C.D. Wu; J.L. Pierson; J.P. Kollath; D.D. Weisenburger; A. Kessinger; J.O. Armitage

High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma
Annals of Oncology 1998;9(9):1023-1026.

51
229.
1998

Steven H. Bernstein; Auayporn P. Nademanee; Julie M. Vose; Guido Tricot; Joseph W. Fay; Robert S. Negrin; John DiPersio; Gabriela Rondon; Richard Champlin; Michael J. Barnett; et al.

A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
Blood 1998;91(9):3509-3517.

72
230.
1998

Julie M. Vose; Philip J. Bierman; James C. Lynch; Dennis D. Weisenburger; Anne Kessinger; Wing C. Chan; Timothy C. Greiner; James O. Armitage

Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology 1998;16(3):844-849.

9
231.
1998

J.M. Vose

Current approaches to the management of non-Hodgkin's lymphoma
Seminars in Oncology 1998;25(4):483-491.

64
232.
1998

J.M. Vose

High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma
Annals of Oncology 1998;9(SUPPL. 1):S1-S3.

23
233.
1998

C.D. Weekes; S.J. Pirruccello; J.M. Vose; C. Kuszynski; J.G. Sharp

Lymphoma cells associated with bone marrow stromal cells in culture exhibit altered growth and survival
Leukemia and Lymphoma 1998;31(1-2):151-165.

9
234.
1998

A. Kessinger; P.J. Bierman; M.K. Cowles; J.R. Anderson; J.O. Armitage; M.R. Bishop; J.M. Vose

Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma: Effect on failure-free survival
Cancer Research, Therapy and Control 1998;5(2):113-119.

4
235.
1998

R.J. Hauke; T.C. Greiner; B.N. Smir; J.M. Vose; S.R. Tarantolo; R.M. Bashir; P.J. Bierman

Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: Report of two cases
Bone Marrow Transplantation 1998;21(12):1271-1274.

37
236.
1998

William D. Haire; Elizabeth I. Ruby; Lana C. Stephens; Elizabeth Reed; Stefano R. Tarantolo; Z. Steven Pavletic; Philip J. Bierman; Michael Bishop; Anne Kessinger; Julie Vose; et al.

A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation 1998;4(3):142-150.

14
237.
1998

Z.S. Pavletic; S.S. Joshi; S.J. Pirruccello; S.R. Tarantolo; J. Kollath; E.C. Reed; P.J. Bierman; J.M. Vose; P.I. Warkentin; et al.

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
Bone Marrow Transplantation 1998;21(1):33-41.

71
238.
1997

Michael R. Bishop; Stefano R. Tarantolo; John D. Jackson; James R. Anderson; Kim Schmit-Pokorny; Diane Zacharias; Zivko S. Pavletic; Samuel J. Pirruccello; Julie M. Vose; Philip J. Bierman; et al.

Allogeneic-blood stem-cell collection following mobilization with low- dose granulocyte colony-stimulating factor
Journal of Clinical Oncology 1997;15(4):1601-1607.

23
239.
1997

Z. Steven Pavletic; Michael R. Bishop; Stefano R. Tarantolo; Salvador Martin-Algarra; Philip J. Bierman; Julie M. Vose; Elizabeth C. Reed; Thomas G. Gross; Jeff Kollath; Khalliq Nasrati; et al.

Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies
Journal of Clinical Oncology 1997;15(4):1608-1616.

104
240.
1997

Julie M. Vose; Arundathy N. Pandite; Roy A. Beveridge; Robert B. Geller; Michael W. Schuster; Jeanne E. Anderson; Charles F. LeMaistre; Tauseef Ahmed; Alberto Granena; Armand Keating; et al.

Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: Results of a randomized double-blind trial
Journal of Clinical Oncology 1997;15(4):1617-1623.

13
241.
1997

P.J. Bierman; J.M. Vose; J.R. Anderson; M.R. Bishop; A. Kessinger; J.O. Armitage

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
Journal of Clinical Oncology 1997;15(2):445-450.

210
242.
1997

J.E. Talmadge; E. Reed; K. Ino; A. Kessinger; C. Kuszynski; D. Heimann; M. Varney; J. Jackson; J.M. Vose; P.J. Bierman

Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
Bone Marrow Transplantation 1997;19(2):161-172.

146
243.
1997

M.A. Shipp; R.F. Ambinder; F.R. Appelbaum; F. Cabanillas; N.J. Harris; G.P. Herzig; R.T. Hoppe; S.J. Horning; R.D. Pezner; et al.

NCCN preliminary Non-Hodgkin's lymphoma practice guidelines
ONCOLOGY 1997;11(11 SUPPL. 11A):281-346.

11
244.
1997

T.M. Waters; C.L. Bennett; J.M. Vose

Economic analyses of new technologies: The case of stem-cell transplantation
Journal of Clinical Oncology 1997;15(1):2-4.

12
245.
1997

Vikki Ann Canfield; Julie Vose; Patricia Guiney; Bronwyn Bennett; Craig Nichols

2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas
Leukemia and Lymphoma 1997;24(3-4):335-339.

12
246.
1997

G.Q. Wu; J.G. Sharp; G. Wu; J. Vose; T.C. Greiner; W.C. Chan

The detection of minimal lymphoma by molecular and combined culture- molecular methods
British Journal of Haematology 1997;99(4):873-881.

12
247.
1996

J.M. Vose; P.J. Bierman; E. Ruby; E.C. Reed; M.R. Bishop; S. Tarantolo; A. Kessinger; J.O. Armitage

Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies
Bone Marrow Transplantation 1996;17(6):951-956.

4
248.
1996

Dennis D. Weisenburger; Bruce G. Gordon; Julie M. Vose; Martin A. Bast; Wing C. Chan; Timothy C. Greiner; James R. Anderson; Warren G. Sanger

Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma
Blood 1996;87(9):3860-3868.

57
249.
1996

B. Jain; A.A. Floreani; J.R. Anderson; J.M. Vose; R.A. Robbins; S.I. Rennard; J.H. Sisson

Cardiopulmonary function and autologous bone marrow transplantation: Results and predictive value for respiratory failure and mortality
Bone Marrow Transplantation 1996;17(4):561-568.

34
250.
1996

P.J. Bierman; J.M. Vose; A.N. Langnas; R.M. Rifkin; R.J. Hauke; B.N. Smir; T.C. Greiner

Hodgkin's disease following solid organ transplantation
Annals of Oncology 1996;7(3):265-270.

28
251.
1996

P.J. Bierman; J.R. Anderson; M.B. Freeman; J.M. Vose; A. Kessinger; M.R. Bishop; J.O. Armitage

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
Annals of Oncology 1996;7(2):151-156.

68
252.
1996

J.M. Vose; J.E. Anderson; P.J. Bierman; F.R. Appelbaum; J.R. Anderson; L. Garrison; M.E. Lebsack; J.O. Armitage

Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy
Journal of Clinical Oncology 1996;14(2):520-526.

12
253.
1996

J.L. Gajewski; G.L. Phillips; K.A. Sobocinski; J.O. Armitage; R.P. Gale; R.E. Champlin; R.H. Herzig; D.D. Hurd; S. Jagannath; J.P. Klein; et al.

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease
Journal of Clinical Oncology 1996;14(2):572-578.

125
254.
1996

M.R. Bishop; J.D. Jackson; B. O'Kane-Murphy; K. Schmit-Pokorny; J.M. Vose; P.J. Bierman; P.I. Warkentin; J.O. Armitage; L. Garrison; A. Kessinger

Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells
Journal of Clinical Oncology 1996;14(9):2521-2526.

20
255.
1996

J.M. Vose

Classification and clinical course of low-grade non-Hodgkin's lymphomas with overview of therapy
Annals of Oncology 1996;7(SUPPL. 6):13-19.

15
256.
1996

M. Markman; D.S. Ettinger; T. Thigpen; C.R. Nichols; A.Y. Chang; G.D. Demetri; J.M. Vose

Discussion: Neurotoxicity of ifosfamide therapy
Seminars in Oncology 1996;23(3 SUPPL. 6):103-104.

1
257.
1996

J.M. Vose

Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma
Seminars in Oncology 1996;23(3 SUPPL. 6):33-37.

9
258.
1996

J.M. Vose; P.J. Bierman; J.R. Andersen; K.A. Harrison; G.V. Dalrymple; K. Byar; A. Kessinger; J.O. Armitage

Single-photon emission computed tomography gallium imaging versus computed tomography: Predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma
Journal of Clinical Oncology 1996;14(9):2473-2479.

52
259.
1995

William D. Haire; Elizabeth I. Ruby; Bruce G. Gordon; Kashinath D. Patil; Lana C. Stephens; Gail D. Kotulak; Elizabeth C. Reed; Julie M. Vose; Philip J. Bierman; et al.

Multiple organ dysfunction syndrome in bone marrow transplantation
Journal of the American Medical Association 1995;274(16):1289-1295.

57
260.
1995

Julie M. Vose; James O. Armitage

Clinical applications of hematopoietic growth factors
Journal of Clinical Oncology 1995;13(4):1023-1035.

97
261.
1995

C.L. Bennett; J.L. Armitage; G.O. Armitage; J.M. Vose; P.J. Bierman; J.O. Armitage; J.R. Anderson

Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987 through 1991
Journal of Clinical Oncology 1995;13(4):969-973.

62
262.
1995

J.M. Vose

Chemotherapeutic palliative approaches in the treatment of lymphoma
Seminars in Oncology 1995;22(SUPPL. 3):53-57.

3
263.
1995

J.M. Vose

Cytokine use in the older patient
Seminars in Oncology 1995;22(1 SUPPL. 1):6-8.

9
264.
1995

D.A. Stewart; J.M. Vose; D.D. Weisenburger; J.R. Anderson; E.I. Ruby; M.A. Bast; P.J. Bierman; A. Kessinger; J.O. Armitage

The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma
Annals of Oncology 1995;6(3):263-266.

80
265.
1995

G.L. Phillips; J. Vose; A. Carella; A. Goldstone; S. Forman; K. Van Besien

Intensive therapy and hematopoietic stem cell rescue in lymphoma: Summary of the Keystone Lymphoma Workshop
Bone Marrow Transplantation 1995;15(SUPPL. 1):S229-S233.

1
266.
1995

A.R. Martin; D.D. Weisenburger; W.C. Chan; E.I. Ruby; J.R. Anderson; J.M. Vose; P.J. Bierman; M.A. Bast; D.T. Daley; et al.

Prognostic value of cellular proliferation and histologic grade in follicular lymphoma
Blood 1995;85(12):3671-3678.

98
267.
1995

Y. Yan; W.C. Chan; D.D. Weisenburger; J.R. Anderson; M.A. Bast; J.M. Vose; P.J. Bierman; J.O. Armitage

Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma
Journal of Clinical Oncology 1995;13(6):1336-1342.

34
268.
1995

W.P. Vaughan; E. Kris; J. Vose; P.J. Bierman; P. Gwilt; J.O. Armitage

Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma
Journal of Clinical Oncology 1995;13(5):1089-1095.

13
269.
1995

A. Kessinger; M.R. Bishop; J.D. Jackson; B. O'Kane-Murphy; J.M. Vose; P.J. Bierman; E.C. Reed; P.I. Warkentin; J.O. Armitage; J.G. Sharp

Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies
Experimental Hematology 1995;23(7):609-612.

22
270.
1995

C.L. Bennett; S.L. George; J.M. Vose; J.J. Nemunaitis; J.L. Armitage; J.O. Armitage; N.C. Gorin; S.C. Gulati

Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trials
Stem Cells 1995;13(4):414-420.

24
271.
1995

J.O. Armitage; P.J. Bierman; J.M. Vose; M.R. Bishop; M.A. Kessinger

Autologous bone marrow transplantation for Hodgkin's disease
Journal of Hematotherapy 1995;4(1):61-62.

2
272.
1995

D.H. Henry; R.I. Abels; J.M. Vose; J.O. Armitage

Benefits of epoetin alfa therapy in anemic cancer patients receiving chemotherapy [4]
Journal of Clinical Oncology 1995;13(9):2473-2474.

2
273.
1995

A. Kessinger; M.R. Bishop; J.R. Anderson; J.O. Armitage; P.J. Bierman; E.C. Reed; S. Tarantolo; M.A. Tempero; J.M. Vose; et al.

Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization
Journal of Hematotherapy 1995;4(2):81-84.

4
274.
1995

J.G. Sharp; M. Bishop; W.C. Chan; T. Greiner; S.S. Joshi; A. Kessinger; E. Reed; W. Sanger; S. Tarantolo; M. Traystman; et al.

Detection of minimal residual disease in hematapoietic tissues
Annals of the New York Academy of Sciences 1995;770():242-261.

9
275.
1995

S. Martin-Algarra; M.R. Bishop; S. Tarantolo; M.K. Cowles; E. Reed; J.R. Anderson; J.M. Vose; P. Bierman; J.O. Armitage; et al.

Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis
Experimental Hematology 1995;23(14):1503-1508.

18
276.
1995

J.M. Vose

Treatment for non-Hodgkin's lymphoma in relapse
New England Journal of Medicine 1995;333(23):1565-1566.

11
277.
1995

J.M. Vose

CHLVPP therapy for Hodgkin's disease identification of prognostic factors
Leukemia and Lymphoma 1995;15(SUPPL. 1):13-14.

2
278.
1995

J.R. Anderson; J.O. Armitage; J.M. Vose; P. Bierman; D. Weisenburger; D. Cunningham; M.E.R. O'Brien; G. Middleton; A. Webb; G.M. Mead; et al.

ChlVPP therapy for Hodgkin's disease: Experience of 960 patients
Annals of Oncology 1995;6(2):167-172.

10
279.
1994

Anne Kessinger; James Armitage; Philip Bierman; Michael Bishop; Shantaram Joshi; Elizabeth Reed; Graham Sharp; James Talmadge; Julie Vose

Clinical outcome of peripheral blood stem cell support
Medical Oncology 1994;11(2):43-46.

14
280.
1994

Michael R. Bishop; James R. Anderson; John D. Jackson; Philip J. Bierman; Elizabeth C. Reed; Julie M. Vose; James O. Armitage; Phyllis I. Warkentin; Anne Kessinger

High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft
Blood 1994;83(2):610-616.

81
281.
1994

D.L. Darrington; J.M. Vose; J.R. Anderson; P.J. Bierman; M.R. Bishop; W.C. Chan; M.E. Morris; E.C. Reed; W.G. Sanger; et al.

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
Journal of Clinical Oncology 1994;12(12):2527-2534.

261
282.
1994

J.M. Vose; J.R. Anderson; P.J. Bierman; M. Bast; D. Weisenburger; W.C. Chan; M.R. Bishop; J.O. Armitage

Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens
Seminars in Hematology 1994;31(2 SUPPL. 3):4-8.

12
283.
1994

P.J. Johnson; W.M. Lydiatt; J.V. Huerter Jr.; F.P. Ogren; J.M. Vose; R.J. Stratta; A.J. Yonkers

Invasive fungal sinusitis following liver or bone marrow transplantation
American Journal of Rhinology 1994;8(2):77-83.

6
284.
1994

Jordan P. Metcalf; Stephen I. Rennard; Elizabeth C. Reed; William D. Haire; Joseph H. Sisson; Trudy Walter; Richard A. Robbins; James O. Armitage; Mark Arneson; Phillip J. Bierman; et al.

Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation
American Journal of Medicine 1994;96(4):327-334.

67
285.
1994

P.J. Bierman; J.M. Vose; J.O. Armitage

Editorial: Autologous transplantation for Hodgkin's disease: Coming of age?
Blood 1994;83(5):1161-1164.

36
286.
1994

W.C. Chan; G.Q. Wu; T.C. Greiner; J.M. Vose; J.G. Sharp

Detection of tumor contamination of peripheral stem cells in patients with lymphoma using cell culture and polymerase chain reaction technology
Journal of Hematotherapy 1994;3(3):175-184.

8
287.
1994

J.R. Anderson; J. Vose; A. Kessinger; J.S. Miller; D.J. Weisdorf

Myelodysplastic syndrome after autologous transplant for lymphoma [7]
Blood 1994;84(11):3988-3989.

8
288.
1994

J.B. Benear; R.J. Winn; C.A. Coltman Jr.; A.C. Smyth; J.S. Bailes; F.A. Greco; D. Kelsen; N. Kemeny; D.J. Adelstein; J.M. Vose; et al.

Discussion
Seminars in Oncology 1994;21(4 SUPPL. 7):123-132.

0
289.
1994

J.O. Armitage; J.M. Vose; P.J. Bierman; M.R. Bishop

Salvage therapy for patients with lymphoma
Seminars in Oncology 1994;21(4 SUPPL. 7):82-85.

8
290.
1993

Susan N. Rabinowe; Donna Neuberg; Philip J. Bierman; Julie M. Vose; John Nemunaitis; Jack W. Singer; Arnold S. Freedman; Peter Mauch; George Demetri; Nicole Onetto; et al.

Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies
Blood 1993;81(7):1903-1908.

30
291.
1993

P.C. Iwen; E.C. Reed; J.O. Armitage; P.J. Bierman; A. Kessinger; J.M. Vose; M.A. Arneson; B.A. Winfield; G.L. Woods

Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1993;14(3):131-139.

72
292.
1993

A. Kessinger; J.M. Vose; P.J. Bierman; M. Bishop; J.O. Armitage

Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients
Journal of Hematotherapy 1993;2(3):361-362.

6
293.
1993

J.M. Vose; J.O. Armitage; A. Kessinger

High-dose chemotherapy and autologous transplant with peripheral-blood stem cells
ONCOLOGY 1993;7(8):23-29.

6
294.
1993

P.J. Bierman; J.M. Vose; P.K. Leichner; S.M. Quadri; J.O. Armitage; J.L. Klein; R.A. Abrams; K.A. Dicke; H.M. Vriesendorp

Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease
Journal of Clinical Oncology 1993;11(4):698-703.

35
295.
1993

J.M. Vose; J.O. Armitage

What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas?
Leukemia and Lymphoma 1993;10(SUPPL.):61-64.

3
296.
1993

J.M. Vose; J.O. Armitage

Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma
Hematology/Oncology Clinics of North America 1993;7(3):577-590.

12
297.
1993

H. Nakamine; R.G. Bagin; J.M. Vose; M.A. Bast; P.J. Bierman; J.O. Armitage; D.D. Weisenburger

Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma
Cancer 1993;71(10):3130-3137.

11
298.
1993

M.R. Bishop; P.J. Bierman; J.M. Vose; J.O. Armitage

The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma
Annals of Oncology 1993;4(SUPPL. 1):1-6.

1
299.
1993

J.M. Vose; E.C. Reed; G.C. Pippert; J.R. Anderson; P.J. Bierman; A. Kessinger; J. Spinolo; J.O. Armitage

Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: A randomized trial
Journal of Clinical Oncology 1993;11(7):1306-1310.

49
300.
1993

P.J. Bierman; R.G. Bagin; S. Jagannath; J.M. Vose; G. Spitzer; A. Kessinger; K.A. Dicke; J.O. Armitage

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients
Annals of Oncology 1993;4(9):767-773.

124
301.
1993

B.G. Gordon; D.D. Weisenburger; P.I. Warkentin; J. Anderson; W.G. Sanger; M. Bast; D. Gnarra; J.M. Vose; P.J. Bierman; et al.

Peripheral T-cell lymphoma in childhood and adolescence: A clinicopathologic study of 22 patients
Cancer 1993;71(1):257-263.

21
302.
1993

J.R. Anderson; J.M. Vose; P.J. Bierman; D.D. Weisenburger; W.G. Sanger; J. Pierson; M. Bast; J.O. Armitage

Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group
Journal of Clinical Oncology 1993;11(2):218-224.

44
303.
1993

Julie M. Vose; James O. Armitage

Bone marrow transplantation for Hodgkin's disease and lymphoma
Annual Review of Medicine 1993;44():255-263.

1
304.
1993

J.M. Vose; J.R. Anderson; A. Kessinger; P.J. Bierman; P. Coccia; E.C. Reed; B. Gordon; J.O. Armitage

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology 1993;11(10):1846-1851.

171
305.
1992

B.G. Gordon; P.I. Warkentin; D.D. Weisenburger; J.M. Vose; W.G. Sanger; S.E. Strandjord; J.R. Anderson; J.D. Verdirame; P.J. Bierman; et al.

Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents
Blood 1992;80(11):2938-2942.

13
306.
1992

A.S. Masih; D.D. Weisenburger; J.M. Vose; M.A. Bast; J.O. Armitage

Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease
Cancer 1992;69(1):228-232.

12
307.
1992

J.M. Vose; P.J. Bierman; J.O. Armitage

Granulocyte-macrophage colony-stimulating factor (GM-CSF): Answers or more questions?
Annals of Internal Medicine 1992;116(3):261-262.

3
308.
1992

J.M. Vose; B.C. Kennedy; P.J. Bierman; A. Kessinger; J.O. Armitage

Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies
Cancer 1992;69(3):784-789.

52
309.
1992

J.H. Sisson; A.B. Thompson; J.R. Anderson; R.A. Robbins; J.R. Spurzem; P.R. Spence; E.C. Reed; J.O. Armitage; J.M. Vose; et al.

Airway inflammation predicts diffuse alveolar hemorrhage during bone marrow transplantation in patients with Hodgkin disease
American Review of Respiratory Disease 1992;146(2):439-443.

22
310.
1992

B. Letheby; J. Jackson; J. Greally; P. Warkentin; D. Smith; J. Vose; P. Bierman; A. Kessinger; P. Coccia; J. Armitage

Comparison of two methods of bone marrow processing for autologous bone marrow transplantation.
Progress in clinical and biological research 1992;377():345-351.

1
311.
1992

S.W. Braddock; D. Harrington; J. Vose

Generalized nodular cutaneous pseudolymphoma associated with phenytoin therapy: Use of T-cell receptor gene rearrangement in diagnosis and clinical review of cutaneous reactions to phenytoin
Journal of the American Academy of Dermatology 1992;27(2 II):337-340.

18
312.
1992

J.M. Vose; P.J. Bierman; J.R. Anderson; A. Kessinger; J. Pierson; J. Nelson; B. Frappier; K. Schmit-Pokorny; D.D. Weisenburger; J.O. Armitage

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up
Blood 1992;80(8):2142-2148.

95
313.
1991

J.M. Vose; J.O. Armitage

The use of GM-CSF in bone marrow transplantation.
Behring Institute Mitteilungen 1991;(90):39-43.

0
314.
1991

John Nemunaitis; Susan N. Rabinowe; Jack W. Singer; Philip J. Bierman; Julie M. Vose; Arnold S. Freedman; Nicole Onetto; Steven Gillis; Dagmar Oette; Morris Gold; et al.

Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer
New England Journal of Medicine 1991;324(25):1773-1778.

188
315.
1991

J.O. Armitage; P.J. Bierman; J.M. Vose; J.R. Anderson; D.D. Weisenburger; A. Kessinger; E.C. Reed; W.P. Vaughan; P.F. Coccia; et al.

Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease
American Journal of Medicine 1991;91(6):605-611.

63
316.
1991

J.M. Vose; P.J. Bierman; J.R. Anderson; D. Weisenburger; D.F. Moravec; S. Sorensen; M. Hutchins; M.D. Dowling; D. Howe; J. Okerbloom; et al.

CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: Favorable results with acceptable toxicity
Journal of Clinical Oncology 1991;9(8):1421-1425.

11
317.
1991

J.M. Vose; P.J. Bierman; D.D. Weisenburger; J.O. Armitage

The therapy of non-Hodgkin's lymphomas: Introduction and overview
Hematology/Oncology Clinics of North America 1991;5(5):845-852.

6
318.
1991

J.M. Vose; J.O. Armitage

New approaches to therapy in patients with lymphoma
Hospital Formulary 1991;26(7):564-570.

2
319.
1991

P.J. Bierman; J.M. Vose; J.O. Armitage

Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: Issues and controversies
Leukemia 1991;5(SUPPL. 1):58-62.

0
320.
1991

R.M. Bashir; P.J. Bierman; J.M. Vose; D.D. Weisenburger; J.O. Armitage

Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma
American Journal of Clinical Oncology: Cancer Clinical Trials 1991;14(6):478-482.

50
321.
1991

A. Kessinger; P.J. Bierman; J.M. Vose; J.O. Armitage

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease
Blood 1991;77(11):2322-2325.

55
322.
1991

B. Coiffier; C. Gisselbrecht; J.M. Vose; H. Tilly; R. Herbrecht; A. Bosly; J.O. Armitage

Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy
Journal of Clinical Oncology 1991;9(2):211-219.

132
323.
1991

J.M. Vose; J.O. Armitage

Diffuse 'histiocytic' lymphoma
Seminars in Oncology 1991;18(1):50-60.

1
324.
1991

A. Kessinger; J.M. Vose; P.J. Bierman; J.O. Armitage

High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: An alternative to bone marrow purging
Experimental Hematology 1991;19(10):1013-1016.

21
325.
1991

J.M. Vose; J.O. Armitage

The present status of therapy for patients with aggressive non-Hodgkin's lymphoma
Annals of Oncology 1991;2(SUPPL. 2):171-176.

6
326.
1991

J.M. Vose; P.J. Bierman; A. Kessinger; P.F. Coccia; J. Andersen; F.B. Oldham; C. Epstein; J.O. Armitage

The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies
Bone Marrow Transplantation 1991;7(2):139-143.

17
327.
1990

J.M. Vose; J.O. Armitage; P.J. Bierman

Bone marrow transplantation for Hodgkin's disease, non-Hodgkin's lymphoma and multiple myeloma.
Cancer treatment and research 1990;50():259-278.

0
328.
1990

H.C. Schouten; D. Maragos; J. Vose; J.O. Armitage

Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation
Bone Marrow Transplantation 1990;6(5):333-335.

6
329.
1990

J.M. Vose; C. Peterson; P.J. Bierman; D.D. Weisenburger; J. Linder; D. Harrington; W.P. Vaughan; A. Kessinger; J.O. Armitage

Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas
Blood 1990;76(2):424-431.

39
330.
1990

J.O. Armitage; J.M. Vose; P.J. Bierman

Salvage therapy for patients with non-Hodgkin's lymphoma
NCI Monographs 1990;(10):39-43.

5
331.
1990

J.M. Vose; D.D. Weisenburger; W.G. Sanger; P.J. Bierman; J.O. Armitage

Peripheral T-cell lymphoma - A brief review
Leukemia and Lymphoma 1990;3(2):77-86.

1
332.
1990

J.M. Vose; P.J. Bierman; J.O. Armitage

Hodgkin's disease: The role of bone marrow transplantation
Seminars in Oncology 1990;17(6):749-757.

4
333.
1989

H.C. Schouten; P.J. Bierman; W.P. Vaughan; A. Kessinger; J.M. Vose; D.D. Weisenburger; J.O. Armitage

Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation
Blood 1989;74(7):2579-2584.

69
334.
1989

J.M. Vose; J.O. Armitage; P.J. Bierman; D.D. Weisenburger; M. Hutchins; M.D. Dowling; D.F. Moravec; S. Sorensen; J. Okerbloom; G. Bascom; et al.

Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation
American Journal of Medicine 1989;87(3):285-288.

24
335.
1989

J.O. Armitage; J.M. Vose; J. Linder; D. Weisenburger; D. Harrington; J. Casey; P. Bierman; S. Sorensen; M. Hutchins; D.F. Moravec; et al.

Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology 1989;7(12):1783-1790.

56
336.
1988

J.M. Vose; J.O. Armitage; M. Duggan; S.W. Braddock

Pyoderma gangrenosum or cutaneous lymphoma: a difficult clinical diagnosis.
Cutis 1988;42(4):335-337.

12
337.
1988

J.M. Vose; J.O. Armitage; D.D. Weisenburger; P.J. Bierman; S. Sorensen; M. Hutchins; D.F. Moravec; D. Howe; M.D. Dowling; J. Mailliard; et al.

The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology 1988;6(12):1838-1844.

131
338.
1988

J. Vose; J. Armitage; D. Weisenburger; D. Moravec; M. Hutchins; D. Howe; S. Sorensen; M. Dowling; J. Okerbloom; W. Pevnick; et al.

ChlVPP - An effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease
American Journal of Clinical Oncology: Cancer Clinical Trials 1988;11(4):423-426.

4
339.
1988

J.O. Armitage; W.G. Sanger; D.D. Weisenburger; D.S. Harrington; J. Linder; P.J. Bierman; J.M. Vose; D.T. Purtilo

Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21)
Journal of the National Cancer Institute 1988;80(8):576-580.

40
340.
1987

J.M. Vose; P.W. Smith; M. Henry; D. Colan

Recurrent streptococcus mutans endocarditis
American Journal of Medicine 1987;82(3 SPEC. ISS.):630-632.

16

Julie Marie Vose University of Nebraska Medical Center, Internal Medicine Oncology/Hematology

Julie Marie Vose

Publications

340 Publications from Scopus

Julie Marie Vose
University of Nebraska Medical Center, Internal Medicine Oncology/Hematology